
Sign up to save your podcasts
Or


Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jared Weiss, GRACE Vice President, and his patient Tomma Hargraves, discuss how they became a team.
Acquired Resistance Forum Video #14: Speakers from video #11 and video #12 at the Acquired Resistance in Lung Cancer Patient Forum sat for a moderated Q&A with Dr. Jack West.
Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.
November is Lung Cancer Awareness Month. To mark it this year, GRACE is celebrating the empowered lung cancer patient. In this video, Dr. Jack West, GRACE founder and president, explains the steps that patients can do become empowered.
Acquired Resistance Forum Video #12: Online advocate and ROS1 patient "Craig In PA" Uthe detailed how patients can educate themselves about their disease to understand and improve their personal situations. He also included his favorite online resources.
Acquired Resistance Forum Video #11: Bonnie J. Addario, founder of the Addario Lung Cancer Foundation described how the lung cancer community can work together to support each other and affect change for all patients.
Acquired Resistance Forum Video #10: Online advocate and ROS1 patient "Craig In PA" Uthe leads a Q&A with speakers from videos #8 and #9 at the Acquired Resistance in Lung Cancer Patient Forum.
Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.
Acquired Resistance Forum Video #8: Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.
From the publisher's feed